Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer

Acta Oncologica

Volumn 52, Issue 8, 2013, Pages 1602-1608

  Hayat Roshanai, Afsaneh ^a,b   Nordin, Karin ^a,c   Berglund, Gunilla ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; DECISION MAKING; FEMALE; GENERAL PRACTITIONER; GROUPS BY AGE; HUMAN; MALE; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; QUESTIONNAIRE; HEALTH STATUS; MAJOR CLINICAL STUDY; PATIENT WORRY; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE;

ADULT; AGE FACTORS; AGED; DECISION MAKING; EARLY DETECTION OF CANCER; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, PRIMARY CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 84885452650     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.762998     Document Type: Article

References (26)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92.
2. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456-77.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
4. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Prostate cancer mor tality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-24.
5. Payne H, Cornford P. Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 2011; 29: 593-601. [Review].
6. Loeb S, Catalona WJ. Prostate-specific antigen screening: Pro. Curr Opin Urol 2010; 20: 185-8.
7. Grubb RL, 3rd, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102: 1524-30.
8. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico A V. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009; 73: 659-64.
9. Socialstyrelsen. Nationella riktlinjer för prostatacancersjukvård-Medicinskt och hälsoekonomiskt faktadokument. 2007.
10. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: What do the patients know? J Cancer Educ 1996; 11: 39-44.
11. Berglund G, Nilsson S, Nordin K. Intention to test for prostate cancer. Eur J Cancer 2005; 41: 990-7.
12. Haggerty J, Tudiver F, Brown JB, Herbert C, Ciampi A, Guibert R. Patients ' anxiety and expectations: How they infl uence family physicians ' decisions to order cancer screening tests. Can Fam Physician 2005; 51: 1658-9.
13. Moran WP, Cohen SJ, Preisser JS, Wofford JL, Shelton BJ, McClatchey MW. Factors infl uencing use of the prostate-specific antigen screening test in primary care. Am J Manag Care 2000; 6: 315-24.
14. Edlefsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N. Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use? Am J Prev Med 1999; 17: 87-90.
15. Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J Gen Intern Med 2001; 16: 831-7.
16. Tudiver F, Guibert R, Hagger ty J, Ciampi A, Medved W, Brown JB, et al. What infl uences family physicians ' cancer screening decisions when practice guidelines are unclear or confl icting? J Fam Pract 2002; 51: 760.
17. Bunting PS, Goel V, Williams JI, Iscoe NA. Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. Can Med Assoc J 1999; 160: 70-5.
18. Curran V, Solberg S, Mathews M, Church J, Buehler S, Wells J, et al. Prostate cancer screening attitudes and continuing education needs of primary care physicians. J Cancer Educ 2005; 20: 162-6.
19. Glanz KRB, Lewis FM. Health behavior and health education: Theory, research, and practice, 3rd ed. San Francisco, California: Jossey-Bas s; 2002.
20. Drummond FJ, Carsin AE, Sharp L, Comber H. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: A national survey of general practitioners. BMC Fam Pract 2009; 10: 3.
21. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007; 167: 2497-502.
22. Stroud L, Ross LE, Rose SW. Formative evaluation of the prostate cancer screening practices of African-American physicians. J Natl Med Assoc 2006; 98: 1637-43.
23. Beaulac JA., Fry RN, Onysko J. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006; 97: 171-6.
24. Gormley GJ, Catney D, McCall JR, Reilly PM, Gavin AT. Prostate-specific antigen testing: Uncovering primary care infl uences. BJU Int 2006; 98: 996-1000.
25. Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001; 16: 391-8.
26. Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med 1999; 8: 333-40.